Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
UBS Initiates Coverage On Shattuck Labs with Buy Rating, Announces Price Target of $17
Wedbush Maintains Outperform on Shattuck Labs, Raises Price Target to $14
Needham Maintains Buy on Shattuck Labs, Raises Price Target to $19
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
Shattuck Labs: A Receptor-Side Bet On The TL1A Boom
What Shattuck Labs Stock Topped the Market on Monday
Raymond James Initiates Coverage On Shattuck Labs with Strong Buy Rating, Announces Price Target of $18
Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?
Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade
HC Wainwright & Co. Maintains Buy on Shattuck Labs, Lowers Price Target to $14
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Shattuck Labs Q2 EPS $(0.12) Misses $(0.10) Estimate
JP Morgan Initiates Coverage On Shattuck Labs with Overweight Rating, Announces Price Target of $10
Leerink Partners Initiates Coverage On Shattuck Labs with Outperform Rating, Announces Price Target of $16
Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update - Slideshow
What's Going On With Shattuck Labs Stock Wednesday?
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.